MoonLake Immunotherapeutics (MLTX) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 5, 2025, to elect three Class III directors, ratify the independent auditor, and hold an advisory vote on executive compensation.

• Shareholders of record as of April 10, 2025, are eligible to vote, with each Class A and Class C share entitled to one vote per proposal.

• The company advanced its lead asset, Sonelokimab (SLK), into late-stage clinical trials and expanded its workforce and capital base in 2024.

Voting matters and shareholder proposals

• Proposals include electing three Class III directors, ratifying Baker Tilly US, LLP as auditor, and an advisory say-on-pay vote.

• The board recommends voting FOR all proposals.

• Shareholders may submit proposals for the 2026 meeting by December 23, 2025, and director nominations between February 5 and March 7, 2026.

Board of directors and corporate governance

• The board consists of six members divided into three classes with staggered three-year terms.

• The nominating committee emphasizes diversity, industry expertise, and governance experience in director selection.

• The board is majority independent, with separate CEO and independent chair roles.

• Committees include Audit, Compensation, and Nominating, each with defined responsibilities and independent members.

• Governance features include a classified board, supermajority voting for key changes, and restrictions on shareholder-initiated meetings.